Search

Your search keyword '"C.L. Bowden"' showing total 29 results
Start Over Author "C.L. Bowden"
29 results on '"C.L. Bowden"'

1. Psychomotor symptoms in major depressive episode are related to bipolarity. A pooled analysis of the BRIDGE and BRIDGE-II-MIX cohorts

Author

Giulio Perugi, G. Maccariello, Cecilia Mainardi, J.-M. Azorin, Jules Angst, Allan H. Young, Sergey Mosolov, C.L. Bowden, Eduard Vieta, Margherita Barbuti, Isabella Pacchiarotti, and Norma Verdolini

Subjects
Pharmacology, Psychomotor learning, medicine.medical_specialty, business.industry, Bridge (interpersonal), Psychiatry and Mental health, Pooled analysis, Neurology, Medicine, Pharmacology (medical), Neurology (clinical), medicine.symptom, business, Psychiatry, Major depressive episode, Biological Psychiatry
Published
2019
Full Text
View/download PDF

3. P.332 Deconstructing major depressive episodes by severity and chronicity: A cross-diagnostic cluster-analysis on a large, international, observational study

Author

Filippo Corponi, Jules Angst, Dina Popovic, Gerard Anmella, Sergey Mosolov, Andrea Murru, Isabella Pacchiarotti, A. Serretti, Norma Verdolini, J.-M. Azorin, Ludovic Samalin, Giulio Perugi, A. Joung, C.L. Bowden, and Eduard Vieta

Subjects
Pharmacology, Psychiatry and Mental health, Neurology, Pharmacology (medical), Observational study, Neurology (clinical), Disease cluster, Psychology, Biological Psychiatry, Clinical psychology
Published
2019
Full Text
View/download PDF

4. P.612 Symptom network structure differences in acute depression between bipolar disorder and major depressive disorder: A network analysis

Author

G. Anmella, F. Corponi, I. Pacchiarotti, N. Verdolini, L. Samalin, D. Popovic, J.M. Azorin, J. Angst, C.L. Bowden, S. Mosolov, A.H. Young, G. Perugi, E. Vieta, A. Serretti, and A. Murru

Subjects
Pharmacology, Psychiatry and Mental health, Neurology, Pharmacology (medical), Neurology (clinical), Biological Psychiatry
Published
2019
Full Text
View/download PDF

5. Hypersomnia as an objective clinical biomarker and prognostic indicator in depressed patients: A post-hoc analysis from the BRIDGE-II- MIX Study

Author

Andrea Murru, G. Guiso, C.L. Bowden, M. Sergey, Isabella Pacchiarotti, Ludovic Samalin, Eduard Vieta, Norma Verdolini, J.-M. Azorin, Giulio Perugi, Dina Popovic, Jules Angst, Allan H. Young, Manuel Valdés, and Margherita Barbuti

Subjects
Pharmacology, medicine.medical_specialty, business.industry, Bridge (interpersonal), Clinical biomarker, Psychiatry and Mental health, Physical medicine and rehabilitation, Neurology, Post-hoc analysis, Medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry
Published
2019
Full Text
View/download PDF

6. The differential role of depressive and manic symptoms in predicting functioning outcome in major depression: A BRIDGE-Mix-II post-hoc analysis

Author

Eduard Vieta, Jules Angst, A. Murru, Ludovic Samalin, Giulio Perugi, Isabella Pacchiarotti, Norma Verdolini, C.L. Bowden, Alberto Aedo, Sergey Mosolov, Allan H. Young, Gerard Anmella, J.-M. Azorin, and Dina Popovic

Subjects
Pharmacology, business.industry, Outcome (game theory), Bridge (interpersonal), Manic symptoms, Psychiatry and Mental health, Neurology, Post-hoc analysis, Medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, Depression (differential diagnoses), Clinical psychology
Published
2019
Full Text
View/download PDF

7. Is aggression a missed bipolar diagnostic feature in mixed depression?

Author

Jules Angst, Ludovic Samalin, Sergey Mosolov, Margherita Barbuti, Giulio Perugi, Allan H. Young, Isabella Pacchiarotti, Norma Verdolini, C.L. Bowden, G. Guiso, Eduard Vieta, Dina Popovic, J.-M. Azorin, and Andrea Murru

Subjects
Pharmacology, Psychiatry and Mental health, Neurology, Feature (computer vision), Aggression, medicine, Pharmacology (medical), Neurology (clinical), medicine.symptom, Psychology, Biological Psychiatry, Depression (differential diagnoses), Clinical psychology
Published
2017
Full Text
View/download PDF

9. ECNP Consensus Meeting March 2000 Nice

Author

W. A. Nlen, J.M. van Ree, A. Saint Raymond, C.L. Bowden, Joseph R. Calabrese, P. Suppes, Gary S. Sachs, Guy M. Goodwin, Roy Chengappa, J. Storosum, Rasmus Wentzer Licht, Jules Angst, and Yves Lecrubier

Subjects
Pharmacology, medicine.medical_specialty, business.industry, Alternative medicine, Nice, medicine.disease, Psychiatry and Mental health, Neurology, Medicine, Pharmacology (medical), Neurology (clinical), Bipolar disorder, business, Psychiatry, computer, Biological Psychiatry, computer.programming_language
Published
2001
Full Text
View/download PDF

10. Hypomanic symptoms in mixed depression: is DSM-5 wrong? Evidence from the BRIDGE-II MIX study

Author

Dina Popovic, J.-M. Azorin, Eduard Vieta, Giulio Perugi, Carla Torrent, Jules Angst, C.L. Bowden, Sergey Mosolov, and Allan H. Young

Subjects
Pharmacology, Psychiatry and Mental health, medicine.medical_specialty, Neurology, medicine, Pharmacology (medical), Neurology (clinical), Psychology, Psychiatry, Bridge (interpersonal), Biological Psychiatry, Depression (differential diagnoses), DSM-5
Published
2016
Full Text
View/download PDF

11. P.2.d.003 Suicidal behaviour in major depressive episode: evidence from the BRIDGE-II-MIX study

Author

Dina Popovic, Jules Angst, Sergey Mosolov, Giulio Perugi, Allan H. Young, C.L. Bowden, Eduard Vieta, and J.-M. Azorin

Subjects
Pharmacology, Psychiatry and Mental health, medicine.medical_specialty, Neurology, medicine, Pharmacology (medical), Neurology (clinical), medicine.symptom, Psychology, Major depressive episode, Psychiatry, Bridge (interpersonal), Biological Psychiatry
Published
2015
Full Text
View/download PDF

12. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression

Author

Rosemary Oakes, Laszlo Gyulai, Dwight L. Evans, I. Gergel, Gary S. Sachs, Charles B. Nemeroff, C.L. Bowden, and Cornelius D. Pitts

Subjects
Adult, Male, medicine.medical_specialty, Imipramine, Bipolar Disorder, Lithium (medication), medicine.drug_class, Antidepressive Agents, Tricyclic, Lithium, Placebo, Gastroenterology, Placebos, Double-Blind Method, Internal medicine, medicine, Ambulatory Care, Humans, Bipolar disorder, Aged, Valproic Acid, Hamilton Rating Scale for Depression, Mood stabilizer, Middle Aged, medicine.disease, Paroxetine, Psychiatry and Mental health, Carbamazepine, Treatment Outcome, Anesthesia, Clinical Global Impression, Anticonvulsants, Drug Therapy, Combination, Female, Psychology, Selective Serotonin Reuptake Inhibitors, medicine.drug
Abstract

Objective: This study compared the efficacy and safety of paroxetine and imipramine with that of placebo in the treatment of bipolar depression in adult outpatients stabilized on a regimen of lithium. Method: In a double-blind, placebo-controlled study, 117 outpatients with DSM-III-R bipolar disorder, depressive phase, were randomly assigned to treatment with paroxetine (N=35), imipramine (N=39), or placebo (N=43) for 10 weeks. In addition to lithium monotherapy, patients may have received either carbamazepine or valproate in combination with lithium for control of manic symptoms. Patients were stratified on the basis of trough serum lithium levels determined at the screening visit (high: >0.8 meq/liter; low: ≤0.8 meq/liter). Primary efficacy was assessed by change from baseline in scores on the Hamilton Rating Scale for Depression and the Clinical Global Impression illness severity scale. Results: Differences in overall efficacy among the three groups were not statistically significant. For patients with high serum lithium levels, antidepressant response at endpoint also did not significantly differ from placebo. However, both paroxetine and imipramine were superior to placebo for patients with low serum lithium levels. Compared to imipramine, paroxetine resulted in a lower incidence of adverse events, most notably emergence of manic symptoms. Conclusions: Antidepressants may not be useful adjunctive therapy for bipolar depressed patients with high serum lithium levels. However, antidepressant therapy may be beneficial for patients who cannot tolerate high serum lithium levels or who have symptoms that are refractory to the antidepressant effects of lithium.

Published
2001

14. P.2.e.01l Characteristics of patients with bipolar disorder presenting a current major depressive episode: analysis in 8 countries

Author

Eduard Vieta, Jules Angst, C.L. Bowden, Allan H. Young, J.-M. Azorin, and Giulio Perugi

Subjects
Pharmacology, medicine.medical_specialty, business.industry, medicine.disease, Psychiatry and Mental health, Prevalence of mental disorders, Neurology, medicine, Pharmacology (medical), Neurology (clinical), Bipolar disorder, medicine.symptom, Psychiatry, Major depressive episode, business, Biological Psychiatry
Published
2009
Full Text
View/download PDF

15. P.2.f.002 Olanzapine versus divalproex and placebo for the treatment of mild to moderate mania associated with bipolar I disorder

Author

H.S. Oliff, Eduard Vieta, S.T. Aaronson, J. Jay Amsterdam, C.L. Bowden, M. Banov, Mauricio Tohen, Ludmila Kryzhanovskaya, B. Sun, and A. Shekhar

Subjects
Pharmacology, Divalproex, Olanzapine, medicine.medical_specialty, Bipolar I disorder, business.industry, medicine.disease, Placebo, Gastroenterology, Psychiatry and Mental health, Neurology, Internal medicine, Medicine, Pharmacology (medical), Neurology (clinical), medicine.symptom, business, Mania, Biological Psychiatry, medicine.drug
Published
2007
Full Text
View/download PDF

16. C.15.03 Bipolar disorder: optimal management strategies

Author

C.L. Bowden

Subjects
Pharmacology, medicine.medical_specialty, business.industry, medicine.disease, Optimal management, Psychiatry and Mental health, Neurology, medicine, Pharmacology (medical), Neurology (clinical), Bipolar disorder, Psychiatry, business, Biological Psychiatry
Published
2007
Full Text
View/download PDF

17. P.1.216 Lamotrigine but not lithium prevents or delays depressive episodes in bipolar I disorder

Author

C.L. Bowden, R. Leadbetter, Guy M. Goodwin, Lakshmi N. Yatham, J. Calabrese, and Robin White

Subjects
Pharmacology, medicine.medical_specialty, Bipolar I disorder, Lithium (medication), business.industry, Lamotrigine, medicine.disease, Gastroenterology, Psychiatry and Mental health, Neurology, Internal medicine, medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, medicine.drug
Published
2003
Full Text
View/download PDF

18. P.1.214 Lamotrigine controls bipolar depression without destabilising mood: An analysis of data from 8 placebo-controlled trials

Author

Susan L. McElroy, Trisha Suppes, Joseph F. Goldberg, C.L. Bowden, Lakshmi N. Yatham, J. Calabrese, and Heinz Grunze

Subjects
Pharmacology, medicine.medical_specialty, business.industry, Lamotrigine, Placebo, Psychiatry and Mental health, Mood, Neurology, Internal medicine, medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, Depression (differential diagnoses), medicine.drug
Published
2003
Full Text
View/download PDF

19. P.1.091 Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial

Author

Robert W. Baker, D. Williamson, Angela R. Evans, Mauricio Tohen, C.L. Bowden, J. Calabrese, T. Jacobs, and J. Chou

Subjects
Pharmacology, Olanzapine, medicine.medical_specialty, business.industry, Relapse prevention, Placebo, medicine.disease, Clinical trial, Double blind, Psychiatry and Mental health, Neurology, Internal medicine, medicine, Pharmacology (medical), Neurology (clinical), Bipolar disorder, business, Biological Psychiatry, medicine.drug
Published
2003
Full Text
View/download PDF

20. Lamotrigine delays mood episodes in recently depressed bipolar I patients

Author

Walter Paska, Gary S. Sachs, C.L. Bowden, John A. Ascher, David S. Baldwin, Kirsten Behnke, Siegfried Kasper, Lakshmi N. Yatham, and J. Calabrese

Subjects
Pharmacology, medicine.medical_specialty, business.industry, Lamotrigine, Psychiatry and Mental health, Mood, Neurology, Medicine, Pharmacology (medical), Neurology (clinical), business, Psychiatry, Biological Psychiatry, medicine.drug
Published
2002
Full Text
View/download PDF

21. Recent maintenance research in bipolar I disorder

Author

C.L. Bowden, Guy M. Goodwin, Siegfried Kasper, Lakshmi N. Yatham, and J. Calabrese

Subjects
Pharmacology, Psychiatry and Mental health, medicine.medical_specialty, Bipolar I disorder, Neurology, business.industry, Medicine, Pharmacology (medical), Neurology (clinical), business, Psychiatry, medicine.disease, Biological Psychiatry
Published
2002
Full Text
View/download PDF

24. P.1.212 Effects of lithium and lamotrigine on body weight after 18 months in bipolar I disorder

Author

C.L. Bowden, G. Evoniuk, Z. Antonijevic, J. Calabrese, and Allan H. Young

Subjects
Pharmacology, medicine.medical_specialty, Bipolar I disorder, Lithium (medication), business.industry, Lamotrigine, medicine.disease, Body weight, Psychiatry and Mental health, Endocrinology, Neurology, Internal medicine, Medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, medicine.drug
Published
2003
Full Text
View/download PDF

25. P.1.210 Concomitant use of lamotrigine and valproate in bipolar I disorder

Author

C.L. Bowden, G. Evoniuk, Gary S. Sachs, and J. Calabrese

Subjects
Pharmacology, medicine.medical_specialty, Bipolar I disorder, business.industry, Lamotrigine, medicine.disease, Psychiatry and Mental health, Endocrinology, Neurology, Internal medicine, Concomitant, medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, medicine.drug
Published
2003
Full Text
View/download PDF

26. P.1.217 Predictors of response to lithium and lamotrigine prophylaxis in bipolar I disorder

Author

C.L. Bowden, R. Leadbetter, Eduard Vieta, Terence A. Ketter, Joseph F. Goldberg, and Z. Antonijevic

Subjects
Pharmacology, medicine.medical_specialty, Bipolar I disorder, Lithium (medication), business.industry, Lamotrigine, medicine.disease, Gastroenterology, Psychiatry and Mental health, Neurology, Internal medicine, medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, medicine.drug
Published
2003
Full Text
View/download PDF

27. P.1.092 Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial

Author

Robert W. Baker, Martin Dossenbach, Robert H. Belmaker, A. Marneros, A. Koukopoulis, Mauricio Tohen, T. Jacobs, Giovanni B. Cassano, Waldemar Greil, Angela R. Evans, D. Williamson, and C.L. Bowden

Subjects
Pharmacology, Olanzapine, Pediatrics, medicine.medical_specialty, Lithium (medication), business.industry, Relapse prevention, medicine.disease, Clinical trial, Double blind, Psychiatry and Mental health, Neurology, medicine, Pharmacology (medical), Neurology (clinical), Bipolar disorder, business, Biological Psychiatry, medicine.drug
Published
2003
Full Text
View/download PDF

28. Lamotrigine or lithium in the maintenance treatment of bipolar I disorder

Author

R. Leadbetter, T. Young, J. Calabrese, C.L. Bowden, R. Fieve, Guy M. Goodwin, and Paul Montgomery

Subjects
Pharmacology, Bipolar I disorder, Lithium (medication), business.industry, Lamotrigine, medicine.disease, Psychiatry and Mental health, Neurology, medicine, Pharmacology (medical), Neurology (clinical), business, Biological Psychiatry, medicine.drug
Published
2002
Full Text
View/download PDF

29. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder

Author

John Cookson, C.L. Bowden, Carolyn Bolden-Watson, John Andersen, John A. Ascher, Linda J. Rhodes, Susan L. McElroy, Jing Zhou, Paul E. Keck, and Joseph R. Calabrese

Subjects
Adult, Male, medicine.medical_specialty, Bipolar Disorder, medicine.drug_class, medicine.medical_treatment, Lamotrigine, Bipolar II disorder, Antimanic Agents, Internal medicine, medicine, Humans, Prospective Studies, Bipolar disorder, Psychiatry, Depression (differential diagnoses), Aged, Psychiatric Status Rating Scales, Triazines, Mood stabilizer, Middle Aged, medicine.disease, Psychiatry and Mental health, Treatment Outcome, Anticonvulsant, Mood, Anticonvulsants, Drug Therapy, Combination, Female, Drug Eruptions, medicine.symptom, Psychology, Mania, medicine.drug
Abstract

New mood stabilizers are needed that possess efficacy for all phases of bipolar disorder. This study was designed to provide preliminary evidence for the safety and efficacy of a new anticonvulsant, lamotrigine, in adult patients with bipolar disorder who had been inadequately responsive to or intolerant of prior pharmacotherapy.A 48-week, open-label, prospective trial was conducted in 75 patients with bipolar I or bipolar II disorder. Lamotrigine was used as adjunctive therapy (N = 60) or monotherapy (N = 15) in patients presenting in depressed, hypomanic, manic, or mixed states.Of the 40 depressed patients included in the efficacy analysis, 48% exhibited a marked response and 20% a moderate response as measured by reductions in 17-item Hamilton Depression Rating Scale scores. Of the 31 with a hypomanic, manic, or mixed state, 81% displayed a marked response and 3% a moderate response on the Mania Rating Scale. From baseline to endpoint, the depressed patients exhibited a 42% decrease in Hamilton depression scale scores, and the patients presenting with hypomania, mania, or a mixed state exhibited a 74% decrease in Mania Rating Scale scores. The most common drug-related adverse events were dizziness, tremor, somnolence, headache, nausea, and rash. Rash was the most common adverse event resulting in drug discontinuation (9% of patients); one patient developed a serious rash and required hospitalization.These open-label data provide preliminary evidence that lamotrigine may be an effective treatment option for patients with refractory bipolar disorder; however, potential benefits must be weighed against potential side effects, including rash.

Catalog

Books, media, physical & digital resources
See catalog results